ADMA Biologics Class Action Lawsuit Deadline Looms for Investors
Investors in ADMA Biologics who experienced substantial losses between August 2024 and March 2026 have an opportunity to lead a class action lawsuit.
ADMA Biologics, Inc. is facing a class action lawsuit alleging violations of securities laws by the company and some of its top executives. The lawsuit targets purchasers or acquirers of the company's publicly traded securities between August 9, 2024, and March 25, 2026. The deadline for investors to seek appointment as lead plaintiff in the case is August 10, 2026.
The lawsuit claims that ADMA Biologics made false and/or misleading statements and failed to disclose crucial information. These allegations include an undisclosed related-party transaction, the use of channel stuffing to inflate revenues, and inadequate internal controls.
The claims gained public attention following a March 24, 2026, report from Culper Research. The report alleged that ADMA Biologics' reported growth was artificially created through channel stuffing and an undisclosed related-party distributor. The company's stock price reportedly declined by over 16% following these allegations.
ADMA Biologics issued a statement refuting the report's claims, calling them speculative and based on unreliable sources. However, subsequent reports indicated that Cantor Fitzgerald downgraded ADMA Biologics' stock rating due to concerns raised by the short-seller report, leading to a further drop in share price.